Literature DB >> 8309576

Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease.

V Meiner1, Z Meiner, A Reshef, I Björkhem, E Leitersdorf.   

Abstract

We report an early molecular diagnosis of cerebrotendinous xanthomatosis (CTX) in a Jewish Moroccan family with two affected siblings. The proband displayed characteristic manifestations of the disease, whereas a younger brother, homozygous for the mutant allele, was asymptomatic. Clinical studies in the younger patient disclosed mild cognitive impairment, peripheral neuropathy, and abnormal EEG. Elevated plasma cholestanol levels were evident in both affected patients, with documented normal levels in the molecularly diagnosed heterozygous family members. Molecular characterization of affected CTX families provides early diagnosis and treatment of homozygotes in the presymptomatic state as well as identification of heterozygotes, which is crucial for genetic counseling and for prenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8309576     DOI: 10.1212/wnl.44.2.288

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjoegren syndrome: a case report.

Authors:  H R Siebner; S Berndt; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

2.  Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27).

Authors:  S Sugama; A Kimura; W Chen; S Kubota; Y Seyama; N Taira; Y Eto
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

3.  Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees.

Authors:  M H Lee; S Hazard; J D Carpten; S Yi; J Cohen; G T Gerhardt; G Salen; S B Patel
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

4.  Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics.

Authors:  E Leitersdorf; R Safadi; V Meiner; A Reshef; I Björkhem; Y Friedlander; S Morkos; V M Berginer
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

5.  Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.

Authors:  M G M de Sain-van der Velden; A Verrips; B H C M T Prinsen; M de Barse; R Berger; G Visser
Journal:  J Inherit Metab Dis       Date:  2008-10-24       Impact factor: 4.982

Review 6.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

Review 7.  Diagnosis of inherited metabolic disorders affecting the nervous system.

Authors:  P D Swanson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

8.  The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature.

Authors:  D Soffer; D Benharroch; V Berginer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 9.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.